Peripheral nerve damage associated with administration of taxanes in patients with cancer

Critical Reviews in Oncology/Hematology

Volumn 66, Issue 3, 2008, Pages 218-228

  Argyriou, Andreas A ^a   Koltzenburg, Martin ^a   Polychronopoulos, Panagiotis ^b   Papapetropoulos, Spiridon ^b   Kalofonos, Haralabos P ^c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Diagnosis; Docetaxel; Neuroprotection; Paclitaxel; Peripheral neuropathy

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AM 424; AMIFOSTINE; AMITRIPTYLINE; ANTIOXIDANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIMESNA; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GABAPENTIN; GLUTAMINE; LAMOTRIGINE; LEUKEMIA INHIBITORY FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; THIOL; VINCA ALKALOID;

ARTHRALGIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL EXAMINATION; CLINICAL TRIAL; DRUG MEGADOSE; ELECTROPHYSIOLOGY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MYALGIA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHWANN CELL; SENSORY NEUROPATHY; SINGLE DRUG DOSE;

ANTINEOPLASTIC AGENTS; HUMANS; INCIDENCE; NEOPLASMS; NEUROPROTECTIVE AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS; TAXOIDS;

EID: 43049128141     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.01.008     Document Type: Review

References (93)

1. Windebank A.J. Chemotherapeutic neuropathy. Curr Opin Neurol 12 (1999) 565-571
2. Rowinsky E.K., and Donehower R.C. Paclitaxel (Taxol). N Engl J Med 332 (1995) 1004-1014
3. Antoine J.C., and Camdessanché J.P. Peripheral nervous system involvement in patients with cancer. Lancet Neurol 6 1 (2007) 75-86
4. Rowinsky E.K., Cazenave L.A., and Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82 (1990) 1247-1259
5. Ibrahim N.K., Desai N., Legha S., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8 5 (2002) 1038-1044
6. Lyseng-Williamson K.A., and Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 65 17 (2005) 2513-2531
7. Hilkens P.H., Verweij J., Vecht C.J., Stoter G., and van den Bent M.J. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 8 2 (1997) 187-190
8. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 249 1 (2002) 9-17
9. Roytta M., Horwitz S.B., and Raine C.S. Taxol-induced neuropathy: short-term effects of local injection. J Neurocytol 13 5 (1984) 685-701
10. Cavaletti G., Cavalletti E., Montaguti P., Oggioni N., De Negri O., and Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18 1 (1997) 137-145
11. Persohn E., Canta A., Schoepfer S., et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 41 10 (2005) 1460-1466
12. Kimura J. Electrodiagnosis in diseases of nerve and muscle, principles and practice. Polyneuropathies. 3rd ed. (2001), Oxford University Press p. 669, [chapter 25]
13. Montero A., Fossella F., Hortobagyi G., and Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6 4 (2005) 229-239
14. Sahenk Z., Barohn R., New P., and Mendell J.R. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51 7 (1994) 726-729
15. Peters C.M., Jimenez-Andrade J.M., Jonas B.M., et al. Intravenous paclitaxel administration in the rat induced a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 203 1 (2007) 42-54
16. Kimura J. Electrodiagnosis in diseases of nerve and muscle, principles and practice. Principles and variations of nerve conduction studies. 3rd ed. (2001), Oxford University Press p. 99-103, [chapter 5]
17. Dustin P. Microtubules. Sci Am 243 (1980) 66-76
18. Nabholtz J.M., Gelmon K., Bontenbal M., et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14 6 (1996) 1858-1867
19. Smith R.E., Brown A.M., Mamounas E.P., et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17 11 (1999) 3403-3411
20. Fountzilas G., Kalofonos H.P., Dafni U., et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15 10 (2004) 1517-1526
21. Chaudhry V., Chaudhry M., Crawford T.O., Simmons-O'Brien E., and Griffin J.W. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60 2 (2003) 337-340
22. Peltier A.C., and Russell J.W. Advances in understanding drug-induced neuropathies. Drug Saf 29 1 (2006) 23-30
23. Lee J.J., and Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24 10 (2006) 1633-1642
24. Winer E.P., Berry D.A., Woolf S., et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22 11 (2004) 2061-2068
25. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17 8 (1999) 2341-2354
26. DeVore III R.F., Jagasia M., and Johnson D.H. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials. Semin Oncol 24 4 Suppl. 12 (1997) S12-27-S12-29
27. Seidman A.D., Berry D.A., Woolf S., et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (s) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 22 Suppl. 14 (2004) 6s [Abstr. 512]
28. du Bois A., Luck H.J., Meier W., et al. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 17 (2003) 1320-1329
29. Chaudhry V., Rowinsky E.K., Sartorius S.E., et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann Neurol 35 (1994) 304-311
30. Viens P., Petit T., Yovine A., et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol 17 3 (2006) 429-436
31. Jamieson S.M., Liu J., Hsu T., Baguley B.C., and McKeage M.J. Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity. Br J Cancer 88 12 (2003) 1942-1947
32. Argyriou A.A., Polychronopoulos P., Iconomou G., Koutras A., Kalofonos H.P., and Chroni E. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 252 12 (2005) 1459-1464
33. Argyriou A.A., Polychronopoulos P., Koutras A., et al. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care 16 3 (2007) 231-237
34. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 11 (2004) 2184-2191
35. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24 18 (2006) 2786-2792
36. Cavaletti G., Bogliun G., Crespi V., et al. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol 15 1 (1997) 199-206
37. Berger T., Malayeri R., Doppelbauer G., et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 33 9 (1997) 1393-1399
38. Akerley W., Herndon J.E., Egorin M.J., et al. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97 10 (2003) 2480-2486
39. Argyriou A.A., Polychronopoulos P., Koutras A., et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?. Support Care Cancer 14 3 (2006) 223-229
40. Cavaletti G., Bogliun G., Marzorati L., et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 61 (2003) 1297-1300
41. National Cancer Institute: Common Toxicity Criteria version 2.0., 1999. Available from http://ctep.cancer.gov/forms/CTCv20.
42. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
43. Ajani J.A., Welch S.R., Raber M.N., et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8 (1990) 147-159
44. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
45. Cornblath D.R., Chaudhry V., Carter K., et al. Total neuropathy score. Validation and reliability study. Neurology 53 (1999) 1660-1664
46. Cavaletti G., Jann S., Pace A., et al., for the Italian NETox Group. Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity. J Periph Nerv Syst 11 (2006) 135-141
47. Cella D. F.A.C.I.T. Manual. Manual of the functional assessment of chronic illness therapy (FACIT) scales (version 4). Center on Outcomes, Research and Education (CORE). Evanston Northwestern Healthcare and Northwestern University; 1997.
48. Huang H.Q., Brady M.F., Cella D., and Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17 2 (2007) 387-393
49. Lauria G., Pareyson D., Grisoli M., et al. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol 47 1 (2000) 104-109
50. Bevilacqua N.J., Rogers L.C., Malik R.A., and Armstrong D.G. Technique of the sural nerve biopsy. J Foot Ankle Surg 46 2 (2007) 139-142
51. Sommer C., and Lauria G. Skin biopsy in the management of peripheral neuropathy. Lancet Neurol 6 7 (2007) 632-642
52. Forsyth P.A., Balmaceda C., Peterson K., et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 35 (1997) 47-53
53. Argyriou A.A., Polychronopoulos P., Koutras A., et al. Peripheral neuropathy induced by administration of cisplatin and paclitaxel-based chemotherapy. Could it be predicted?. Support Care Cancer 13 8 (2005) 647-651
54. Holmes F.A., Walters R.S., Theriault R.L., Forman A.D., Newton L.K., et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83 24 (1991) 1797-1805
55. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., et al. Clinical toxicities encountered by paclitaxel (Taxol). Semin Oncol 20 Suppl. 3 (1993) 1-15
56. New P.Z., Jackson C.E., Rinaldi D., Burris H., and Barohn R.J. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 46 1 (1996) 108-111
57. Wiernik P.H., Schwartz E.L., Strauman J.J., Dutcher J.P., Lipton R.B., and Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47 9 (1987) 2486-2493
58. Ohsumi S., and Sunada Y. Techniques for the neurological examination of taxane-induced neuropathy. Breast Cancer 11 1 (2004) 86-91
59. Schaumburg H.H., and Spencer P.S. Toxic neuropathies. Neurology 29 (1979) 429-431
60. Lipton R.B., Apfel S.C., Dutcher J.P., et al. Taxol produces a predominantly sensory neuropathy. Neurology 39 3 (1989) 368-373
61. Freilich R.J., Balmaceda C., Seidman A.D., Rubin M., and DeAngelis L.M. Motor neuropathy due to docetaxel and paclitaxel. Neurology 47 1 (1996) 115-118
62. Barohn R.J. Approach to peripheral neuropathy and neuronopathy. Semin Neurol 18 1 (1998) 7-18
63. Gregg R.W., Molepo J.M., Monpetit V.J., et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurological tissue and morphological evidence of toxicity. J Clin Oncol 10 (1992) 795-803
64. Rowinsky E.K., McGuire W.P., Guarnieri T., Fisherman J.S., Christian M.C., and Donehower R.C. Cardiac disturbances during the administration of taxol. J Clin Oncol 9 9 (1991) 1704-1712
65. 2 over 3 h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol 127 1 (2001) 55-58
66. Grunberg S.M., Sonka S., Stevenson L.L., and Muggia F.M. Progressive paraesthesias after cessation of therapy with very high dose cisplatin. Cancer Chemother Pharmacol 25 (1989) 62-64
67. Thigpen J.T. Dose-intensity in ovarian carcinoma: hold, enough?. J Clin Oncol 15 4 (1997) 1291-1293
68. Seidman A.D., Hudis C.A., Albanell J., et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16 10 (1998 Oct) 3353-3361
69. Nguyen V.H., and Lawrence H.J. Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22 9 (2004) 1767-1769
70. Savarese D., Boucher J., and Corey B. Glutamine treatment of paclitaxel-induced myalgias and arthralgias. J Clin Oncol 16 12 (1998) 3918-3919
71. Jacobson S.D., Loprinzi C.L., Sloan J.A., Wilke J.L., Novotny P.J., et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 1 4 (2003) 274-278
72. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., and Belinson J. Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol 72 1 (1999) 100-101
73. Apfel S.C. Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. Cancer Invest 18 6 (2000) 564-573
74. Konings P.N., Makkink W.K., van Delft A.M., and Ruigt G.S. Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res 640 1-2 (1994) 195-204
75. Apfel S.C., Lipton R.B., Arezzo J.C., and Kessler J.A. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 29 1 (1991) 87-90
76. Drubin D.G., Feinstein S.C., Shooter E.M., and Kirschner M.W. Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assembly-promoting factors. J Cell Biol 101 5 Pt 1 (1985) 1799-1807
77. Verstappen C.C., Postma T.J., Geldof A.A., and Heimans J.J. Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. Anticancer Res 24 4 (2004) 2337-2341
78. Hilpert F., Stahle A., Tome O., et al. Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy-a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 13 10 (2005) 797-805
79. Openshaw H., Beamon K., Synold T.W., et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 10 2 (2004) 461-467
80. Leong S.S., Tan E.H., Fong K.W., et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21 9 (2003) 1767-1774
81. Lorusso D., Ferrandina G., Greggi S., et al. Multicenter Italian Trials in Ovarian Cancer invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 14 7 (2003) 1086-1093
82. Moore D.H., Donnelly J., McGuire W.P., et al. Gynecologic Oncology Group. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 21 22 (2003) 4207-4213
83. Kilpatrick T.J., Phan S., Reardon K., Lopes E.C., and Cheema S.S. Leukaemia inhibitory factor abrogates Paclitaxel-induced axonal atrophy in the Wistar rat. Brain Res 911 2 (2001) 163-167
84. Davis I.D., Kiers L., MacGregor L., et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 11 5 (2005) 1890-1898
85. Boyle F.M., Wheeler H.R., and Shenfield G.M. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 41 2 (1999) 107-116
86. Vahdat L., Papadopoulos K., Lange D., et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 7 5 (2001) 1192-1197
87. Stubblefield M.D., Vahdat L.T., Balmaceda C.M., Troxel A.B., Hesdorffer C.S., and Gooch C.L. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 17 4 (2005) 271-276
88. Pisano C., Pratesi G., Laccabue D., et al. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-l-carnitine. Clin Cancer Res 9 15 (2003) 5756-5767
89. Flatters S.J., Xiao W.H., and Bennett G.J. Acetyl-l-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett 397 3 (2006) 219-223
90. Bianchi G., Vitali G., Caraceni A., et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine. Eur J Cancer 41 12 (2005) 1746-1750
91. Maestri A., De Pasquale Ceratti A., Cundari S., Zanna C., Cortesi E., and Crino L. A pilot study on the effect of acetyl-l-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 91 2 (2005) 135-138
92. Argyriou A.A., Chroni E., Koutras A., et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage 32 3 (2006) 237-244
93. Argyriou A.A., Chroni E., Koutras A., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64 1 (2005) 26-31